Gujarat Themis Biosyn Limited
Kotak Mahindra Life Insurance added over 1.17% of Gujarat Themis Biosyn during the quarter and now holds 2.17%, or 28,24,859 shares.
A pharmaceutical manufacturer incorporated in 1981, Gujarat Themis Biosyn produces finished Active Pharmaceutical Ingredients through advanced fermentation-based processes. The company specializes in biosynthetic drug compounds for both domestic and international markets. Its proprietary fermentation expertise, vertical integration in API manufacturing, and focus on complex molecule production distinguish it within India's competitive pharmaceutical sector.
Wholly owned subsidiary of Kotak Mahindra Bank. Crossed Rs 1 lakh crore in AUM in November 2025, the 25th year of operations, with a 19% CAGR since 2010. CIO Radhavi Deshpande joined from Kotak Mahindra Bank's proprietary trading desk in April 2021 and runs a disciplined large and midcap equity book.